drugset
drugset / Trial / NCT00830960

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

NCT00830960 ↗

Phase 3 Completed 720 enrolled Eli Lilly and Company Daiichi Sankyo · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.

Timeline

Start
2009-02
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg Oral
Subject Prasugrel Small molecule 5 mg Oral
Subject Prasugrel Small molecule 7.5 mg Oral
Subject Prasugrel Small molecule 10 mg Oral

Indications

acute coronary syndrome